BACKGROUND: The only successful HIV vaccine trial to date is the RV144 trial of the ALVAC/AIDSVAX vaccine in Thailand, which showed an overall incidence reduction of 31%. Most cases were prevented in the first year, suggesting a rapidly waning efficacy. Here, we predict the population level impact and cost-effectiveness of practical implementation of such a vaccine in a setting of a generalised epidemic with high HIV prevalence and incidence. METHODS: We used STDSIM, an established individual-based microsimulation model, tailored to a rural South African area with a well-functioning HIV treatment and care programme. We estimated the impact of a single round of mass vaccination for everybody aged 15-49, as well as 5-year and 2-year re-vaccination strategies for young adults (aged 15-29). We calculated proportion of new infections prevented, cost-effectiveness indicators, and budget impact estimates of combined ART and vaccination programmes. RESULTS: A single round of mass vaccination with a RV144-like vaccine will have a limited impact, preventing only 9% or 5% of new infections after 10 years at 60% and 30% coverage levels, respectively. Revaccination strategies are highly cost-effective if vaccine prices can be kept below 150 US$/vaccine for 2-year revaccination strategies, and below 200 US$/vaccine for 5-year revaccination strategies. Net cost-savings through reduced need for HIV treatment and care occur when vaccine prices are kept below 75 US$/vaccine. These results are sensitive to alternative assumptions on the underlying sexual network, background prevention interventions, and individual's propensity and consistency to participate in the vaccination campaign. DISCUSSION: A modestly effective vaccine can be a cost-effective intervention in highly endemic settings. To predict the impact of vaccination strategies in other endemic situations, sufficient knowledge of the underlying sexual network, prevention and treatment interventions, and individual propensity and consistency to participate, is key. These issues are all best addressed in an individual-based microsimulation model. Crown
BACKGROUND: The only successful HIV vaccine trial to date is the RV144 trial of the ALVAC/AIDSVAX vaccine in Thailand, which showed an overall incidence reduction of 31%. Most cases were prevented in the first year, suggesting a rapidly waning efficacy. Here, we predict the population level impact and cost-effectiveness of practical implementation of such a vaccine in a setting of a generalised epidemic with high HIV prevalence and incidence. METHODS: We used STDSIM, an established individual-based microsimulation model, tailored to a rural South African area with a well-functioning HIV treatment and care programme. We estimated the impact of a single round of mass vaccination for everybody aged 15-49, as well as 5-year and 2-year re-vaccination strategies for young adults (aged 15-29). We calculated proportion of new infections prevented, cost-effectiveness indicators, and budget impact estimates of combined ART and vaccination programmes. RESULTS: A single round of mass vaccination with a RV144-like vaccine will have a limited impact, preventing only 9% or 5% of new infections after 10 years at 60% and 30% coverage levels, respectively. Revaccination strategies are highly cost-effective if vaccine prices can be kept below 150 US$/vaccine for 2-year revaccination strategies, and below 200 US$/vaccine for 5-year revaccination strategies. Net cost-savings through reduced need for HIV treatment and care occur when vaccine prices are kept below 75 US$/vaccine. These results are sensitive to alternative assumptions on the underlying sexual network, background prevention interventions, and individual's propensity and consistency to participate in the vaccination campaign. DISCUSSION: A modestly effective vaccine can be a cost-effective intervention in highly endemic settings. To predict the impact of vaccination strategies in other endemic situations, sufficient knowledge of the underlying sexual network, prevention and treatment interventions, and individual propensity and consistency to participate, is key. These issues are all best addressed in an individual-based microsimulation model. Crown
Authors: Till Bärnighausen; David E Bloom; David Canning; Abigail Friedman; Orin S Levine; Jennifer O'Brien; Lois Privor-Dumm; Damian Walker Journal: Vaccine Date: 2010-12-13 Impact factor: 3.641
Authors: Caroline Jehu-Appiah; Rob Baltussen; Charles Acquah; Moses Aikins; Salassi Amah d'Almeida; William K Bosu; Xander Koolman; Jeremy Lauer; Dan Osei; Sam Adjei Journal: Value Health Date: 2008-12 Impact factor: 5.725
Authors: Frank Tanser; Victoria Hosegood; Till Bärnighausen; Kobus Herbst; Makandwe Nyirenda; William Muhwava; Colin Newell; Johannes Viljoen; Tinofa Mutevedzi; Marie-Louise Newell Journal: Int J Epidemiol Date: 2007-11-12 Impact factor: 7.196
Authors: Debby C J Vissers; Hélène A C M Voeten; Nico J D Nagelkerke; J Dik F Habbema; Sake J de Vlas Journal: PLoS One Date: 2008-05-07 Impact factor: 3.240
Authors: Kobus Herbst; Matthew Law; Pascal Geldsetzer; Frank Tanser; Guy Harling; Till Bärnighausen Journal: Curr Opin HIV AIDS Date: 2015-11 Impact factor: 4.283
Authors: Xiao Zang; Emanuel Krebs; Linwei Wang; Brandon D L Marshall; Reuben Granich; Bruce R Schackman; Julio S G Montaner; Bohdan Nosyk Journal: Pharmacoeconomics Date: 2019-10 Impact factor: 4.981
Authors: Jan A C Hontelez; Sake J de Vlas; Rob Baltussen; Marie-Louise Newell; Roel Bakker; Frank Tanser; Mark Lurie; Till Bärnighausen Journal: AIDS Date: 2012-07-31 Impact factor: 4.177
Authors: Joshua T Herbeck; Kathryn Peebles; Paul T Edlefsen; Morgane Rolland; James T Murphy; Geoffrey S Gottlieb; Neil Abernethy; James I Mullins; John E Mittler; Steven M Goodreau Journal: Vaccine Date: 2017-12-11 Impact factor: 3.641
Authors: Jeffrey W Eaton; Leigh F Johnson; Joshua A Salomon; Till Bärnighausen; Eran Bendavid; Anna Bershteyn; David E Bloom; Valentina Cambiano; Christophe Fraser; Jan A C Hontelez; Salal Humair; Daniel J Klein; Elisa F Long; Andrew N Phillips; Carel Pretorius; John Stover; Edward A Wenger; Brian G Williams; Timothy B Hallett Journal: PLoS Med Date: 2012-07-10 Impact factor: 11.069
Authors: Alethea W McCormick; Nadia N Abuelezam; Erin R Rhode; Taige Hou; Rochelle P Walensky; Pamela P Pei; Jessica E Becker; Madeline A DiLorenzo; Elena Losina; Kenneth A Freedberg; Marc Lipsitch; George R Seage Journal: PLoS One Date: 2014-05-27 Impact factor: 3.240
Authors: Jan A C Hontelez; Mark N Lurie; Till Bärnighausen; Roel Bakker; Rob Baltussen; Frank Tanser; Timothy B Hallett; Marie-Louise Newell; Sake J de Vlas Journal: PLoS Med Date: 2013-10-22 Impact factor: 11.069